医学
物理疗法
肌萎缩
随机对照试验
置信区间
日常生活活动
前瞻性队列研究
内科学
作者
Rui‐Li Wang,Yuxiang Liang,J. Jiang,M. Chen,Longjiang Li,Hui Jun Yang,Lu Tan,Ming Jen Yang
标识
DOI:10.1007/s12603-020-1429-x
摘要
OBJECTIVES: To assess the effectiveness of short-term exercise for treating sarcopenia in hospitalized older patients aged 80 years and over. DESIGN: Prospective clinical trial. SETTING: A post-acute care unit. PARTICIPANTS: Sarcopenic patients aged 80 years or over. INTERVENTIONS: The participants were allocated to the intervention group (to receive a mixed exercise program with 10 sessions over two weeks) or the control group (usual care) based on the sequence of admission. OUTCOMES: The primary outcome was the improvement in activities of daily living (ADL) estimated by the change in Barthel Index (BI) score from the baseline to the end of the 2-week intervention. The secondary outcomes were the changes in gait speed, handgrip strength, the time "UP and GO" test (TUG) score, and the Short Physical Performance Battery (SPPB) score. RESULTS: We included 121 participants (intervention group: n = 62; control group: n = 59). All participants in the intervention group finished all 10 exercise sessions. After the 2-week intervention, patients in the mixed exercise group achieved a significant improvement in ADL compared with their counterparts in the control group (the adjusted mean difference of the change in BI score was 7.8 points, 95% confidence interval (CI) 4.0 to 11.8 points). The mixed exercise program significantly but slightly improved gait speed (adjusted group difference in mean change: 0.06 m/s, 95% CI 0.02 to 0.11 m/s). However, the mixed exercise program did not significantly improve the handgrip strength, SPPB score, or TUG score compared with usual care. CONCLUSION: Very old inpatients with sarcopenia can benefit from a mixed exercise program (even as short as two weeks) by improving their ADL and gait speed. However, the long-term effects of exercise on important clinical outcomes need to be further evaluated.
科研通智能强力驱动
Strongly Powered by AbleSci AI